Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5420568 | 0.77 | CHRM2 (0.50) | LSSCHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL5650254 | 0.76 | LSS (0.57) | LSSCHRM3CHRM2CHRM1CHRNA7 | |
| SCHEMBL5648831 | 0.73 | LSS (0.54) | LSSCHRM3CHRM2CHRM1CHRNA7 | |
| Fumaric Acid SCHEMBL5417065 | 0.72 | LSS (0.50) | LSSCHRM3CHRM2CHRM1CHRNA7 | |
| Fumaric Acid SCHEMBL5417070 | 0.72 | LSS (0.50) | LSSCHRM3CHRM2CHRM1CHRNA7 | |
| Fumaric Acid SCHEMBL5650192 | 0.72 | LSS (0.50) | LSSCHRM3CHRNA7BCHEACHE | |
| Fumaric Acid SCHEMBL5650201 | 0.72 | LSS (0.50) | LSSCHRM3CHRNA7BCHEACHE | |
| SCHEMBL4136890 | 0.71 | LSS (0.57) | LSSCHRNA7BCHEACHE | |
| SCHEMBL5429441 | 0.71 | LSS (0.42) | LSSCHRM3CHRM2CHRM1CHRNA7 | |
| Hydrochloric Acid SCHEMBL5710706 | 0.70 | LSS (0.52) | LSSCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137398-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA1, CHRNA2, CHRM2 | LSS 2314/4885CHRM3 6/4885CHRM2 3/4885 |
| US-20050137226-A1 | 3-Quinuclidinyl heteroatom bridged biaryl derivatives | CHRNA3, CHRNA1, CHRM3 | LSS 1730/4885CHRM3 3/4885CHRM2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.